Pharma News, 2025

Beijing institute launches AI platform to boost new-drug development

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis

Novartis and UK-based Relation forge R&D deal worth up to $1.7bn

Io Therapeutics, Inc., presents today at the San Antonio Breast Cancer Symposium preclinical studies demonstrating effectiveness of IRX4204, the company’s clinical stage retinoid X nuclear receptor ...

Plasma p-tau217 can reliably detect preclinical Alzheimer disease

Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA

Amneal stock rises after FDA approves epinephrine injection

BIOSECURE Act set for Congress vote after inclusion in annual defence bill

Lunai Bioworks Advances Parkinson’s Subtype Targets Toward Preclinical Validation

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer

The UK and US have agreed to keep tariffs on UK pharmaceutical shipments into the US at zero.

Pseudomonas aeruginosa – one of the most common hospital germs – has sophisticated mechanisms to efficiently infect the human body and evade the immune system or antibiotics.